Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban for acute cerebral infarction beyond IV thrombolysis window
ChiCTR2300075991Phase 4Not yet recruiting
- Sponsor
- Tianjin TEDA Hospital
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tirofiban in brain infarction and ischemic stroke (2 arms), sponsored by Tianjin TEDA Hospital. Primary endpoints: NIHSS score change and mRS score. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
brain infarctionischemic stroke
Beyond the preview
Go deeper on ChiCTR2300075991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075991.